Novartis gets the GIST as Glivec label expanded to three years
This article was originally published in Scrip
Executive Summary
Following a priority review, the US FDA has approved an update to the Glivec/Gleevec (imatinib) label to recommend three years of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST).